A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (NCT05535244)

🧪 Interventions in This Study

• Cevostamab (DRUG)
• Tocilizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (27 Sites)

Showing the first 25 of 27 sites.

• University of Colorado — Aurora, Colorado
• Mayo Clinic-Jacksonville — Jacksonville, Florida
• University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
• Dana Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic - Rochester — Rochester, Minnesota
• Icahn School of Medicine at Mount Sinai (ISMMS) — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Tennessee Oncology - Nashville — Nashville, Tennessee
• Hunstman Cancer Institute — Salt Lake City, Utah
• Calvary Mater Newcastle — Waratah, New South Wales
• St Vincent's Hospital Melbourne — Fitzroy, Victoria
• UZ Leuven Gasthuisberg — Leuven,
• CHU NANTES - Hôtel Dieu — Nantes,
• APHP - Hospital Saint Louis — Paris,
• CHU de Poitiers - La Miletrie — Poitiers,
• Klinik der Uni zu Köln — Cologne,
• Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II — Hamburg,
• Universitätsklinikum Würzburg — Würzburg,
• Hadassah Ein Karem Hospital — Jerusalem,
• Sheba Medical Center — Ramat Gan,
• Sourasky Medical Centre — Tel Aviv,
• Policlinico S.Orsola-Malpighi — Bologna, Emilia-Romagna
• Asst Papa Giovanni Xxiii — Bergamo, Lombardy
• Fond. IRCCS Istituto Nazionale Tumori — Milan, Lombardy
• A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette — Turin, Piedmont

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.